DexCom Inc. (NASDAQ:DXCM) insider John Lister sold 3,560 shares of the company’s stock in a transaction that occurred on Friday, September 9th. The stock was sold at an average price of $93.65, for a total value of $333,394.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of DexCom Inc. (NASDAQ:DXCM) opened at 93.06 on Monday. The stock has a 50 day moving average price of $91.35 and a 200-day moving average price of $74.57. The stock’s market cap is $7.81 billion. DexCom Inc. has a 12-month low of $47.92 and a 12-month high of $103.29.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 2nd. The medical device company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.12) by $0.12. The firm had revenue of $137.30 million for the quarter, compared to analyst estimates of $132.48 million. DexCom had a negative return on equity of 19.68% and a negative net margin of 16.42%. The business’s quarterly revenue was up 47.3% on a year-over-year basis. During the same period in the previous year, the business posted ($0.05) EPS. Equities analysts anticipate that DexCom Inc. will post ($0.57) EPS for the current fiscal year.

DXCM has been the subject of a number of research analyst reports. Wedbush restated an “outperform” rating and issued a $112.00 target price on shares of DexCom in a research report on Wednesday, June 15th. JPMorgan Chase & Co. restated a “buy” rating on shares of DexCom in a research report on Monday, June 20th. Zacks Investment Research downgraded DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, June 28th. Canaccord Genuity restated a “buy” rating and issued a $95.00 target price on shares of DexCom in a research report on Wednesday, July 13th. Finally, Jefferies Group restated a “buy” rating and issued a $98.00 target price (up from $90.00) on shares of DexCom in a research report on Friday, July 15th. Four research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $94.96.

Hedge funds have recently bought and sold shares of the company. BlackRock Fund Advisors raised its stake in DexCom by 0.6% in the first quarter. BlackRock Fund Advisors now owns 929,897 shares of the medical device company’s stock valued at $63,149,000 after buying an additional 5,443 shares during the last quarter. BlackRock Group LTD raised its stake in DexCom by 17.6% in the first quarter. BlackRock Group LTD now owns 69,904 shares of the medical device company’s stock valued at $4,747,000 after buying an additional 10,465 shares during the last quarter. BlackRock Inc. raised its stake in DexCom by 314.5% in the first quarter. BlackRock Inc. now owns 9,321 shares of the medical device company’s stock valued at $633,000 after buying an additional 7,072 shares during the last quarter. Franklin Resources Inc. raised its stake in DexCom by 7.7% in the first quarter. Franklin Resources Inc. now owns 1,476,904 shares of the medical device company’s stock valued at $100,296,000 after buying an additional 106,215 shares during the last quarter. Finally, Prudential Financial Inc. raised its stake in DexCom by 37.9% in the first quarter. Prudential Financial Inc. now owns 138,269 shares of the medical device company’s stock valued at $9,390,000 after buying an additional 38,032 shares during the last quarter. 99.50% of the stock is owned by institutional investors.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.

5 Day Chart for NASDAQ:DXCM

Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.